AngioWaveNet vs SignalHF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Angiowave Imaging
VS
by Implicity

AI Verdict

AngioWaveNet is an AI tool designed to enhance fluoroscopic angiograms for improved vessel visualization during cardiac catheterization procedures. In contrast, SignalHF is an AI algorithm that predicts heart failure hospitalizations by analyzing data from cardiac implantable electronic devices. While both are FDA-cleared AI solutions for cardiology, AngioWaveNet focuses on image enhancement for interventional diagnostics, whereas SignalHF provides predictive analytics for proactive patient management.

Choose AngioWaveNet if…

Choose AngioWaveNet if your primary objective is to enhance the clarity and detail of fluoroscopic angiograms during cardiac catheterization or other interventional procedures. This tool is ideal for cath labs and interventional suites seeking improved real-time vessel visualization to optimize procedural outcomes and potentially reduce contrast usage.

View AngioWaveNet →

Choose SignalHF if…

Choose SignalHF if your focus is on proactively managing heart failure patients with cardiac implantable electronic devices (CIEDs) to prevent hospitalizations. This AI algorithm is best suited for cardiology practices and heart failure clinics aiming to identify high-risk patients early, enabling timely interventions and personalized care plans based on predictive analytics.

View SignalHF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AngioWaveNet SignalHF
Pricing Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. Contact for pricing
Deployment Cloud-based or on-premise/servers SaaS
FDA Status 1 AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AngioWaveNet

AngioWaveNet emphasizes minimal training and automatic post-processing that integrates seamlessly into existing Cath lab workflows, allowing clinicians to review enhanced images without delaying procedures. Its rapid configuration and 'no downtime' approach suggest a very low barrier to adoption and immediate usability within a busy clinical environment.

Clinical Value

SignalHF

SignalHF offers a compelling clinical value by predicting heart failure hospitalizations within 30 days, enabling early intervention and personalized care. This proactive approach has been associated with a 26% reduced mortality and a 4% reduction in hospitalization length, demonstrating a significant impact on patient outcomes and healthcare burden.

Pricing & Value

AngioWaveNet

AngioWaveNet offers transparent pricing options, including annual software licensing or subscription-based access, which can be tailored to cath lab volume and hospital needs. This clear articulation of pricing models provides greater clarity and flexibility for potential customers compared to SignalHF's unspecified 'contact for pricing' approach.

Enterprise Readiness

AngioWaveNet

Both tools are FDA-cleared and HIPAA compliant, demonstrating a strong commitment to regulatory standards. However, AngioWaveNet offers deployment flexibility with both cloud-based and on-premise/server options, which caters to a wider range of enterprise IT infrastructure and data governance requirements, giving it a slight advantage in enterprise readiness.

Innovation

SignalHF

SignalHF demonstrates greater innovation by leveraging AI for predictive analytics, specifically to forecast heart failure hospitalizations within 30 days by analyzing diverse data from cardiac implantable electronic devices. This represents a proactive and cutting-edge application of AI in healthcare, moving beyond image enhancement to enable early intervention and personalized preventative care.

Support & Docs

SignalHF

Implicity, the company behind SignalHF, offers a highly detailed and comprehensive support structure, including a dedicated Customer Success team, tailored training, regular activity reviews, and responsive expert support. Furthermore, their 'Full Solution' option integrates a certified clinical review service, providing a more extensive and hands-on support ecosystem that can significantly streamline operations for healthcare providers.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AngioWaveNet SignalHF
Name AngioWaveNet SignalHF
Primary Function Enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories. Predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices.
Company Angiowave Imaging Implicity
Compatibility Compatible with any fluoroscopic angiography system (vendor-agnostic); Functions as a DICOM endpoint for imaging systems. Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs).
Key Technology/Method AI-powered Spatiotemporal Enhancement Processing (STEPu2122); Post-processing AI for angiographic images. FDA-cleared AI algorithm for heart failure prediction; Analyzes physiological data, demographics, lead measurements, episodes, and therapies.
Specialties Cardiology, Interventional Radiology, Vascular Surgery Cardiology

Videos

Demos, reviews, and walkthroughs featuring AngioWaveNet and SignalHF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AngioWaveNet integrates into existing Cath lab workflows as a post-processing AI and DICOM endpoint, directly improving vessel visualization during fluoroscopic angiograms. SignalHF analyzes data from cardiac implantable electronic devices to generate automatic alerts for care teams, enabling early intervention to prevent heart failure hospitalizations.
AngioWaveNet functions as a DICOM endpoint for imaging systems, primarily handling image data within the Cath lab environment. SignalHF generates automatic alerts for care teams, implying integration with clinical workflows for alert delivery and management, though specific EHR integration depth is not detailed.
AngioWaveNet focuses on providing 'improved vessel visualization' in fluoroscopic angiograms, but specific quantitative accuracy or sensitivity metrics are not provided in its description. SignalHF aims to 'predict heart failure hospitalizations within 30 days,' though specific performance metrics for its predictive accuracy are not detailed.
For AngioWaveNet, as a post-processing tool integrating into existing Cath lab workflows, the learning curve for staff is likely minimal, with immediate benefits in enhanced image quality. SignalHF requires staff to understand and act on AI-generated risk scores and alerts, potentially involving a new workflow, with value realized through reduced hospitalizations over time.
AngioWaveNet offers both cloud-based and on-premise deployment options, providing flexibility to accommodate different site requirements during a multi-site rollout. SignalHF utilizes a SaaS deployment model, which inherently supports scalability and centralized management for efficient multi-site implementations.

Backers

Who funded each tool's parent company.

SignalHF

AI Tool Finder
AI-powered search. Results may not be comprehensive.